logo
Scientists Found 52-Foot-Tall Underground Ripples From the Asteroid That Killed the Dinosaurs

Scientists Found 52-Foot-Tall Underground Ripples From the Asteroid That Killed the Dinosaurs

Yahoo12-03-2025

Some 66 million years after the Chicxulub asteroid impact kickstarted the Cretaceous–Paleogene (K-T) extinction, scientists are still finding stunning evidence of its destruction.
In 2021, researchers spotted 'megaripples' nearly one mile below the surface, suggesting that the megatsunami created by the impact left behind geologic formations as the waves collided with the continental shelf.
Now, the authors have expanded the search and found evidence of megaripples in a 900-square-mile area throughout the Gulf of Mexico, along with their varying formations along the upper shelf and the deep sea.
Of the five mass extinctions that have impacted our planet in the past 500 million years, the Cretaceous–Paleogene (K-T) extinction event certainly delivers on dramatic flair. On a spring day some 66 million years ago, a six-mile-wide asteroid smashed down just north of what is now Mexico's Yucatan Peninsula. This sudden impact created tsunamis stretching one mile tall and racing outward from the asteroid's dino-killing blow. As those waves raced toward present-day Louisiana (which was largely underwater at the time), they achieved most of their gargantuan height as they reached the ramp of the continental shelf.
In 2021, using seismic data gathered by the oil and natural gas company Devon Energy, scientists led by Gary Kinsland from the University of Louisiana at Lafayette found evidence of this geologic trauma in the form of 52-foot-tall 'megaripples' located one mile underground—an area of rock associated with the end-Cretaceous period. Initially surveying a 77-mile area, Kinsland and his team determined that these subterranean ripples likely formed as the asteroid-generated megatsunamis disturbed sediment near the shore.
Now, a new study from the same team reveals that these 'megaripples'—roughly spaced up to one kilometer apart—can be found both further up the shelf of what is now central Louisiana and further down in deeper waters of the Gulf of Mexico. The scientists behind this new paper found evidence of megaripples in a larger, 900-square-mile area, and explain that these formations vary depending on where the tsunami impacted sediments along the paleo-shelf. The results of the study were published in the journal Marine Geology.
'The megaripples are different on the slope, at the shelf break and further up the shelf,' Kinsland, the lead author of the new study, told Live Science. 'This is important information in modeling of tsunami, in prediction of future tsunami interactions with shelves and in the understanding of the Chicxulub tsunami.'
As the study explains, the largest of these megaripples can be seen along the paleo-shelf break—the area where the Gulf's depth dramatically increases down the slope of the continental shelf toward the deep sea. The way that waves interact with the continental shelf is a well-known process known as the 'Van Dorn effect,' which describes how waves surge over a shelf. The study also discovered that megaripples further inland were more weakly asymmetric, suggesting the waves' behavior changed as they entered shallower waters. Conversely, megaripples in the deep sea took on varied shapes, likely as a result of interactions with faults and collapses, according to Live Science.
'From the coverage of the three areas here in Louisiana we infer that the buried northern Gulf of Mexico shelf system, from Texas to Florida, is covered with megaripples from at least the paleo-slope up to the paleo-bathymetry where Gulf storms would have eroded the megaripples after their formation,' the team said in a press statement.
While this gives scientists a better understanding of how the Chicxulub impact tsunami affected the region, it also provides a stunningly powerful example of how tsunamis interact with continental shelves. And if our worst fears are ever realized, it may help us prepare for future asteroid encounters during Earth's never-ending journey through the universe.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zion museum's new temporary exhibit delves into research on end-Triassic extinction
Zion museum's new temporary exhibit delves into research on end-Triassic extinction

Yahoo

time11 hours ago

  • Yahoo

Zion museum's new temporary exhibit delves into research on end-Triassic extinction

SPRINGDALE, Utah () — A new, temporary exhibit featuring research on the Triassic and Jurassic periods is available at the Zion Human History Museum. It features research on geoscience and extinction, as well as a model phytosaur skull. The new exhibit will bring guests through the late Triassic period, the end-Triassic Extinction, and the beginnings of the Jurassic period, between 227 to 180 million years ago. This is the culmination of a seven-year research project involving scientists from all over. Dr. Celina Suarez, a geoscience professor at the University of Arkansas, led the team. The rocks at Zion National Park were key to this research, as they were used to study and understand the climate change that led to the end-Triassic Extinction. Two Utah campgrounds included in list of 50 Favorite Places to Camp in America Right Now: Hipcamp According to a press release from Zion National Park, Dr. Suarez and her team identified 'a spike in CO2 levels in the park's Moenave Formation.' Using this information, the scientists were able to pinpoint a rapid increase in volcanic eruptions that led to the supercontinent Pangea splitting. 'We've got to look at the geologic past and all these past events to understand where we're going in the future,' Dr. Suarez is quoted in a press release. 'If we can just get one or two people that come and visit Zion to understand that … I've done my job.' Alongside that discovery, which is mirrored in sites all around the world, Dr. Suarez and the team of scientists found that the CO2 spike would also cause wildfires and 'intense weather patterns' that led to the End Triassic Extinction, which wiped out 'approximately 80 percent of all marine and terrestrial species on Earth,' according to the release. 10 hikes with stunning wildflowers across Utah The new exhibit at the Zion History Museum was built on this research, and was created by a collaboration between scientists, artists, and partners. Zion National Park extends a special thanks to the Zion Forever Project, St. George Dinosaur Discovery Museum, the Utah Geological Survey and the National Science Foundation in their release. 'None of us could have done anything to this scale by ourselves,' Robyn Henderek, the park's physical scientist, is quoted. 'We all had a role to play in this process.' For more information about visiting this new exhibit, visit . Orangutan at Utah's Hogle Zoo expecting baby this month Trump and Musk feud escalates Tariff battle continues Zion museum's new temporary exhibit delves into research on end-Triassic extinction One person dead following accident on Highway 89 near Utah-Sanpete county line Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Yahoo

time2 days ago

  • Yahoo

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif., June 04, 2025--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. "We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization," said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. "As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation." At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. "I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome," said Steve Gavel, Chief Commercial Officer at Orca Bio. "The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer." Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. "I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function," said Allison Frisbee, Senior Vice President, Legal at Orca Bio. "It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients." About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners. View source version on Contacts Corporate CommunicationsKelsey Grossmanmedia@ Investor RelationsJoshua Murrayir@

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Business Wire

time2 days ago

  • Business Wire

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. 'We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization,' said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. 'As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation.' At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. 'I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome,' said Steve Gavel, Chief Commercial Officer at Orca Bio. 'The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer.' Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. 'I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function,' said Allison Frisbee, Senior Vice President, Legal at Orca Bio. 'It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients.' About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store